CommercialCoverageMedium impact
08.00.74aa, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology, Pharmacy·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
This policy, effective October 1, 2025, establishes coverage and billing guidelines for intravitreal injections of VEGF antagonists, VEGF biosimilars, and combination VEGF/Ang-2 inhibitors used to treat retinal conditions. The billing team must review the full policy text to identify specific prior authorization requirements, covered medications, dosing limits, and any billing code updates that may affect claim processing for these ophthalmic pharmacy procedures.
Action Required
By October 1, 2025: Billing team must access the full policy text at the source URL to extract specific CPT/HCPCS codes, prior authorization requirements, and coverage criteria for intravitreal VEGF antagonist injections. Update billing system rules, prior authorization workflows, and provider education materials to reflect any changes. Ophthalmology practices must ensure providers document medical necessity per policy requirements. Failure to comply with new prior authorization or billing requirements may result in claim denials. Note: The provided policy summary does not include specific codes or requirements; obtain the complete policy document immediately to implement necessary changes.